None listed
Conditions
Brief summary
The study aimed to evaluate the efficacy of treatment with anti-oxidants in presbycusis, or deafness in the elderly. For this, the volunteers will be divided into four groups and each group will receive one of the following medications: ginkgo biloba, alpha lipoic acid + vitamin C, vitamin E + papaverine and placebo. After six months the hearing will be tested and compared with an initial test to check for hearing improvement with any of these therapies.
Interventions
There are four treatment groups. Group 1: ginkgo biloba, Group 2: alpha lipoic acid with vitamin C, Group 3: papaverine hydrochloride with vitamin E, and Group 4 (Comparator): starch pill. Dry extract of ginkgo biloba 120 mg once a day, oral tablet taken daily for a total of 6 months, alpha lipoic acid 60 mg in combination with vitamin C 600 mg once a day, oral tablet taken daily for a total of 6 months, and vitamin E 400 mg combined with papaverine hydrochloride 100 mg once a day, oral tablet t
There are four treatment groups. Group 1: ginkgo biloba, Group 2: alpha lipoic acid with vitamin C, Group 3: papaverine hydrochloride with vitamin E, and Group 4 (Comparator): starch pill. Dry extract of ginkgo biloba 120 mg once a day, oral tablet taken daily for a total of 6 months, alpha lipoic acid 60 mg in combination with vitamin C 600 mg once a day, oral tablet taken daily for a total of 6 months, and vitamin E 400 mg combined with papaverine hydrochloride 100 mg once a day, oral tablet taken daily for a total of 6 months.
Sponsors
CDA
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used)
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Adults with diagnosis of presbycusis by hearing tests and clinical evaluation.
Exclusion criteria
Will be excluded individuals with other causes for hearing loss, known allergy to any substances in question or with medical contraindications to using them. Patients taking anticoagulants or with coagulation disorders and diabetics will also be excluded from the sample.
Outcome results
None listed